Among TP53-mutated MDS and AML-MRC patients, the combination of azacitidine/magrolimab showed a response rate of about 40%, which is similar to TP53-unmutated patients with anemia due to hemolysis being a well-described side effect [174]. The gene discussed is TP53; the disease is anemia.